WHWK Insider Caley Castelein Buys 38,040 Shares

Caley Castelein acquired 38,040 shares of Whitehawk Therapeutics, Inc. (WHWK) on June 12, 2026. This transaction occurred at a time when the company’s stock was trading on the Nasdaq Capital Market near $4.16 per share. While the specific purchase price was not disclosed in the filing, the acquisition follows a series of similar moves by other leadership figures at the company.

Broad Insider Buying Activity

Castelein was not alone in adding to their position. On June 12, 2026, six other insiders also acquired exactly 38,040 shares each. These individuals include Mohammad Hirmand, Behzad Aghazadeh, Baiteng Zhao, Richard Maroun, Emma Reeve, and Neil Desai. None of these transactions were conducted under a Rule 10b5-1 trading plan, which is a pre-set schedule for trading shares. This group buy-in suggests a shared move among the company's leadership to increase their equity holdings simultaneously.

Whitehawk Therapeutics Stock Levels

On Monday, Whitehawk Therapeutics shares were priced at $4.16. This puts the stock roughly in the middle of its 52-week range, where it has hit a low of $1.82 and a high of $5.50 over the past year. The current price sits above the 200-day moving average of $3.71, though it has recently dipped below the 50-day moving average of $4.29. The company has a current ratio of 17.38, which shows it has plenty of cash and short-term assets to cover its immediate bills.

Analysts Set New Price Targets

Several investment firms have recently started following the company with positive expectations. On October 1, 2026, Stifel initiated coverage with a Buy rating and a $9.00 price target. Earlier, on July 13, 2026, Leerink Partners assigned an Outperform rating with a $9.00 target. B. Riley Securities also initiated coverage on June 25, 2026, setting a higher price target of $10.00. Across six analysts who follow the stock, the average price target is $7.50, suggesting they see room for the stock to rise from its current levels.

Company Background

Whitehawk Therapeutics is a clinical-stage biotechnology company focused on fighting cancer. Based in Morristown, New Jersey, the firm develops antibody-drug conjugates, which are specialized treatments designed to target tumor biology directly. Formerly known as Aadi Bioscience, the company rebranded in 2021 to focus on its current portfolio of oncology technologies. The recent insider buying comes as the company continues to advance these cancer-fighting programs.

Looking Forward

Investors can expect the next major update from the company when it reports its financial results, which is scheduled for November 5, 2026. While the heavy insider buying in June indicates that leadership is increasing its stake, these filings only show what happened on the transaction date and may not reflect where these insiders stand today. The company is currently not profitable, reporting a loss of $1.21 per share, so future earnings will be a key factor for those watching the stock.